Tenofovir Af + Emtricitabine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Tenofovir AF 25 mg + Emtricitabine 200 mg
Reference Brands: Descovy(EU & US)
Category: Anti Viral
Tenofovir Alafenamide (TAF) + Emtricitabine, sold as Descovy, is a once-daily HIV-1 treatment and PrEP option. It offers strong viral suppression with improved kidney and bone safety compared to TDF-based regimens. FDA and EMA approved. Tenofovir AF + Emtricitabine is available in Tablet and strengths such as Tenofovir AF 25 mg + Emtricitabine 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tenofovir AF + Emtricitabine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Tenofovir AF + Emtricitabine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Tenofovir Alafenamide (TAF) + Emtricitabine is a modern, once-daily antiretroviral combination used for the treatment and prevention of HIV-1 infection. Marketed under the brand name Descovy, this formulation offers a safer alternative to TDF-based regimens, with improved renal and bone safety. TAF is a prodrug of tenofovir, delivering effective viral suppression at a lower dose. Combined with Emtricitabine, an NRTI, it forms the backbone of several HIV therapies like Biktarvy, Genvoya, and Odefsey. Approved by the FDA and EMA, TAF + Emtricitabine is also used in PrEP to reduce the risk of HIV transmission in high-risk populations.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tenofovir alafenamide + emtricitabine is used for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) to prevent HIV in high-risk individuals. It helps suppress viral replication and supports long-term HIV management.
It is made from two active ingredients: tenofovir alafenamide (TAF), a nucleotide reverse transcriptase inhibitor, and emtricitabine, a nucleoside reverse transcriptase inhibitor. Together they prevent the virus from multiplying.
The main trade name is Descovy in the USA, EU, and UK.
Descovy is manufactured by Gilead Sciences.
The generic name is tenofovir alafenamide + emtricitabine.
The primary brand name is Descovy.
It is manufactured by Gilead Sciences in the USA and EU, with additional production through authorized global partners.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
